{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:48:00Z","timestamp":1790844480788,"version":"4.1.0"},"reference-count":226,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2018.4283","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T10:56:05Z","timestamp":1519383365000},"source":"Crossref","is-referenced-by-count":4,"title":["Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review)"],"prefix":"10.3892","author":[{"given":"Jorge","family":"Scutti","sequence":"first","affiliation":[{"name":"Immunotherapy Platform, Immunology Department, MD Anderson Cancer Center, Houston, TX 77054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"key20200713184553_b1-ijo-52-04-1041","volume-title":"The Emperor of All Maladies","author":"Mukherjee","year":"2010"},{"key":"key20200713184553_b2-ijo-52-04-1041","unstructured":"National Cancer Institute (NCI)https:\/\/www.cancer.gov"},{"key":"key20200713184553_b3-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/PPO.0b013e318292e4e3","article-title":"Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer","volume":"19","author":"Willers","year":"2013","journal-title":"Cancer J"},{"key":"key20200713184553_b4-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"key20200713184553_b5-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12935-015-0221-1","article-title":"Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp","volume":"15","author":"Alfarouk","year":"2015","journal-title":"Cancer Cell Int"},{"key":"key20200713184553_b6-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6604510","article-title":"Resistance to chemotherapy: New treatments and novel insights into an old problem","volume":"99","author":"Raguz","year":"2008","journal-title":"Br J Cancer"},{"key":"key20200713184553_b7-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1349-7006.2003.tb01345.x","article-title":"Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal","volume":"94","author":"Tsuruo","year":"2003","journal-title":"Cancer Sci"},{"key":"key20200713184553_b8-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"key20200713184553_b9-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"The hallmarks of cancer: The next generation","volume":"5","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"key20200713184553_b10-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers (Basel)"},{"key":"key20200713184553_b11-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.mam.2010.04.001","article-title":"Signal transduction therapy of cancer","volume":"31","author":"Levitzki","year":"2010","journal-title":"Mol Aspects Med"},{"key":"key20200713184553_b12-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A Review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"key":"key20200713184553_b13-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.3390\/biomedicines5020034","article-title":"The role of angiogenesis in cancer treatment","volume":"5","author":"Rajabi","year":"2017","journal-title":"Biomedicines"},{"key":"key20200713184553_b14-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"key20200713184553_b15-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"key20200713184553_b16-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"key20200713184553_b17-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann NY Acad Sci"},{"key":"key20200713184553_b18-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"key20200713184553_b19-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"key20200713184553_b20-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/10408360902937809","article-title":"Cancer immunotherapy","volume":"46","author":"Baxevanis","year":"2009","journal-title":"Crit Rev Clin Lab Sci"},{"key":"key20200713184553_b21-ijo-52-04-1041","unstructured":"Cancer Research Institute (CRI)https:\/\/www.cancerresearch.org"},{"key":"key20200713184553_b22-ijo-52-04-1041","unstructured":"Immunotherapy MD Anderson Cancer Center (MDACC)https:\/\/www.mdanderson.org\/treatment-options\/immunotherapy.html"},{"key":"key20200713184553_b23-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.molonc.2015.10.009","article-title":"Cancer immunotherapy: Strategies for personalization and combinatorial approaches","volume":"9","author":"Sathyanarayanan","year":"2015","journal-title":"Mol Oncol"},{"key":"key20200713184553_b24-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: The beginning of the end of cancer","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"key20200713184553_b25-ijo-52-04-1041"},{"key":"key20200713184553_b26-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"key20200713184553_b27-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrclinonc.2017.64","article-title":"Immunotherapy: A CAR T-cell recipe for success","volume":"14","author":"Romero","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713184553_b28-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"key20200713184553_b29-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"key20200713184553_b30-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"key20200713184553_b31-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"key20200713184553_b32-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"key20200713184553_b33-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b34-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"key20200713184553_b35-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"e27255","DOI":"10.4161\/onci.27255","article-title":"Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity","volume":"3","author":"Thomas","year":"2014","journal-title":"Oncoimmunology"},{"key":"key20200713184553_b36-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.4049\/jimmunol.1300409","article-title":"Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice","volume":"191","author":"He","year":"2013","journal-title":"J Immunol"},{"key":"key20200713184553_b37-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-016-0146-9","article-title":"Cancer immunotherapy trials: Leading a paradigm shift in drug development","volume":"4","author":"Emens","year":"2016","journal-title":"J Immunother Cancer"},{"key":"key20200713184553_b38-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fonc.2015.00117","article-title":"4-1BB agonists: Multi-potent potentiators of tumor immunity","volume":"5","author":"Bartkowiak","year":"2015","journal-title":"Front Oncol"},{"key":"key20200713184553_b39-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00262-016-1829-2","article-title":"4-1BB agonism: Adding the accelerator to cancer immunotherapy","volume":"65","author":"Chester","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713184553_b40-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"E5290","DOI":"10.1073\/pnas.1514418112","article-title":"Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6\/E7 peptide vaccine","volume":"112","author":"Bartkowiak","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b41-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.06.028","article-title":"Rationale for anti-GITR cancer immunotherapy","volume":"67","author":"Knee","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20200713184553_b42-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fonc.2015.00034","article-title":"OX40 agonists and combination immunotherapy: Putting the pedal to the metal","volume":"5","author":"Linch","year":"2015","journal-title":"Front Oncol"},{"key":"key20200713184553_b43-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b44-ijo-52-04-1041","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2017.35.15_suppl.8503","article-title":"Nivolumab (Nivo) + Ipilimumab (Ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from checkmate 032","volume":"35","author":"Hellman","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b45-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer","volume":"35","author":"Govindan","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b46-ijo-52-04-1041","unstructured":"Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)NCT: 02553642. Available at Clinical Trial.gov"},{"key":"key20200713184553_b47-ijo-52-04-1041","unstructured":"Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO. NCT:03387761)Available at ClinicalTrial.gov"},{"key":"key20200713184553_b48-ijo-52-04-1041","unstructured":"Ipilimumab + Androgen Deprivation Therapy in Prostate CancerNCT:01377389. Available at ClinicalTrial.gov"},{"key":"key20200713184553_b49-ijo-52-04-1041","volume-title":"Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: Preliminary findings","author":"Reddy"},{"key":"key20200713184553_b50-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1758834016679942","article-title":"Nivolumab in renal cell carcinoma: Latest evidence and clinical potential","volume":"9","author":"Mazza","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"key20200713184553_b51-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.tranon.2016.01.003","article-title":"PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy","volume":"9","author":"Sorensen","year":"2016","journal-title":"Transl Oncol"},{"key":"key20200713184553_b52-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"57826","DOI":"10.18632\/oncotarget.18406","article-title":"The efficacy of anti-PD-1\/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer","volume":"8","author":"Sheng","year":"2017","journal-title":"Oncotarget"},{"key":"key20200713184553_b53-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"key20200713184553_b54-ijo-52-04-1041","unstructured":"Immunotherapy strategies. Extracted from Society for Immunotherapy for Cancerhttps:\/\/www.sitcancer.org\/home"},{"key":"key20200713184553_b55-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713184553_b56-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b57-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/sj.leu.2403240","article-title":"Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas","volume":"18","author":"Muris","year":"2004","journal-title":"Leukemia"},{"key":"key20200713184553_b58-ijo-52-04-1041","first-page":"5132","article-title":"Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity","volume":"61","author":"Nakano","year":"2001","journal-title":"Cancer Res"},{"key":"key20200713184553_b59-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-12-3847","article-title":"Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin","volume":"19","author":"Remark","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b60-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1620\/tjem.191.113","article-title":"Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis","volume":"191","author":"Mori","year":"2000","journal-title":"Tohoku J Exp Med"},{"key":"key20200713184553_b61-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12531","article-title":"Introduction to checkpoint inhibitors and cancer immunotherapy","volume":"276","author":"Sharpe","year":"2017","journal-title":"Immunol Rev"},{"issue":"Suppl 6","key":"key20200713184553_b62-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"vi88","DOI":"10.1093\/neuonc\/now212.367","article-title":"IMST-11: Downregulation of sphin-gosine-1-phosphate receptor type 1 mediates bone marrow T-cell sequestration in patients and mice with glioblastoma","volume":"18","author":"Chongsathidkiet","year":"2016","journal-title":"Neuro Oncol"},{"key":"key20200713184553_b63-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res"},{"key":"key20200713184553_b64-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1227\/NEU.0b013e31828cf945","article-title":"Expression of indoleamine 2.3-dioxygenase and correlation with pathological malignancy in gliomas","volume":"72","author":"Mitsuka","year":"2013","journal-title":"Neurosurgery"},{"key":"key20200713184553_b65-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2176\/nmc.ra.2017-0010","article-title":"The 2016 WHO classification of tumors of the central nervous system: The major points of revision","volume":"57","author":"Komori","year":"2017","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"key20200713184553_b66-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"key20200713184553_b67-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0360-3016(97)00572-5","article-title":"Pediatric brain stem gliomas: A review","volume":"40","author":"Freeman","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20200713184553_b68-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s003810050205","article-title":"Pediatric brain stem gliomas: An update","volume":"14","author":"Rubin","year":"1998","journal-title":"Childs Nerv Syst"},{"key":"key20200713184553_b69-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3171\/jns.1993.78.3.0408","article-title":"Brain-stem glioma growth patterns","volume":"78","author":"Epstein","year":"1993","journal-title":"J Neurosurg"},{"key":"key20200713184553_b70-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000121011","article-title":"Practical decisions in the treatment of pediatric brain stem tumors","volume":"24","author":"Epstein","year":"1996","journal-title":"Pediatr Neurosurg"},{"key":"key20200713184553_b71-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1212\/WNL.44.10.1798","article-title":"Cervicomedullary tumors in children: A distinct subset of brainstem gliomas","volume":"44","author":"Robertson","year":"1994","journal-title":"Neurology"},{"key":"key20200713184553_b72-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3171\/jns.1993.78.6.0859","article-title":"The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas","volume":"78","author":"Pollack","year":"1993","journal-title":"J Neurosurg"},{"key":"key20200713184553_b73-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/1097-0142(20001001)89:7<1569::AID-CNCR22>3.0.CO;2-0","article-title":"A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities","volume":"89","author":"Fisher","year":"2000","journal-title":"Cancer"},{"key":"key20200713184553_b74-ijo-52-04-1041","first-page":"205","article-title":"DIPG: Poised for progress","volume":"2","author":"Warren","year":"2012","journal-title":"Front Oncol"},{"key":"key20200713184553_b75-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","article-title":"DIPG in children - what can we learn from the past","volume":"5","author":"Vanan","year":"2015","journal-title":"Front Oncol"},{"key":"key20200713184553_b76-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrneurol.2017.39","article-title":"Neuro-oncology: New therapeutic targets for diffuse intrinsic pontine glioma","volume":"13","author":"Ridler","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"key20200713184553_b77-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/pr.2013.194","article-title":"Children are not just little adults: Recent advances in understanding of diffuse intrinsic pontine glioma biology","volume":"75","author":"Schroeder","year":"2014","journal-title":"Pediatr Res"},{"key":"key20200713184553_b78-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b79-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"key20200713184553_b80-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/ng.2995","article-title":"Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat Genet"},{"key":"key20200713184553_b81-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2017.10.013","article-title":"Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG)","volume":"120","author":"Gwak","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20200713184553_b82-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"key20200713184553_b83-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/pbc.25224","article-title":"Diffuse intrinsic pontine glioma biopsy: A single institution experience","volume":"62","author":"Wang","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"key20200713184553_b84-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3171\/2012.10.PEDS12142","article-title":"Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children","volume":"11","author":"Anderson","year":"2013","journal-title":"J Neurosurg Pediatr"},{"key":"key20200713184553_b85-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1101657108","article-title":"Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma","volume":"108","author":"Monje","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b86-ijo-52-04-1041","first-page":"148","article-title":"Future clinical trials in DIPG: Bringing epigenetics to the clinic","volume":"5","author":"Morales","year":"2015","journal-title":"Front Oncol"},{"key":"key20200713184553_b87-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"key20200713184553_b88-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/sj.jid.5701216","article-title":"Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma","volume":"128","author":"Murakami","year":"2008","journal-title":"J Invest Dermatol"},{"key":"key20200713184553_b89-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J Immunol"},{"key":"key20200713184553_b90-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","article-title":"Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate","volume":"65","author":"Armeanu","year":"2005","journal-title":"Cancer Res"},{"key":"key20200713184553_b91-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.18632\/oncotarget.2289","article-title":"HDAC inhibitors and immunotherapy; a double edged sword","volume":"5","author":"Kroesen","year":"2014","journal-title":"Oncotarget"},{"key":"key20200713184553_b92-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature16939","article-title":"Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid","volume":"530","author":"Schl\u00e4ger","year":"2016","journal-title":"Nature"},{"key":"key20200713184553_b93-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"key20200713184553_b94-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1084\/jem.20142290","article-title":"A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J Exp Med"},{"key":"key20200713184553_b95-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2017.72.8089","article-title":"Immunotherapy for brain tumors","volume":"35","author":"Sampson","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b96-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3171\/2008.11.PEDS08281","article-title":"Treatment of diffuse intrinsic brainstem gliomas: Failed approaches and future strategies","volume":"3","author":"Frazier","year":"2009","journal-title":"J Neurosurg Pediatr"},{"key":"key20200713184553_b97-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7150\/jca.20059","article-title":"Cancer vaccine: Learning lessons from immune checkpoint inhibitors","volume":"9","author":"Ye","year":"2018","journal-title":"J Cancer"},{"key":"key20200713184553_b98-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"key20200713184553_b99-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/14728214.2012.679929","article-title":"Recent developments on immunotherapy for brain cancer","volume":"17","author":"Wainwright","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20200713184553_b100-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-011-0776-1","article-title":"Medulloblasoma: Challenges for effective immunotherapy","volume":"108","author":"Sonabend","year":"2012","journal-title":"J Neurooncol"},{"key":"key20200713184553_b101-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"16013","DOI":"10.1073\/pnas.0500090102","article-title":"The response of autologous T cells to a human melanoma is dominated by mutated neoantigens","volume":"102","author":"Lennerz","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b102-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00002371-200501000-00007","article-title":"Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy","volume":"28","author":"Zhou","year":"2005","journal-title":"J Immunother"},{"key":"key20200713184553_b103-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-016-0107-3","article-title":"Novel technologies and emerging biomarkers for personalized cancer immunotherapy","volume":"4","author":"Yuan","year":"2016","journal-title":"J Immunother Cancer"},{"key":"key20200713184553_b104-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"262","DOI":"10.21037\/atm.2016.06.17","article-title":"Neoantigen-based cancer immunotherapy","volume":"4","author":"Bobisse","year":"2016","journal-title":"Ann Transl Med"},{"key":"key20200713184553_b105-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cr.2016.155","article-title":"Immune targets and neoantigens for cancer immunotherapy and precision medicine","volume":"27","author":"Wang","year":"2017","journal-title":"Cell Res"},{"key":"key20200713184553_b106-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/0008-5472.CAN-07-3095","article-title":"Epitope landscape in breast and colorectal cancer","volume":"68","author":"Segal","year":"2008","journal-title":"Cancer Res"},{"key":"key20200713184553_b107-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"key20200713184553_b108-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"key20200713184553_b109-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.2013.54.0526","article-title":"Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas","volume":"32","author":"Pollack","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b110-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/neuonc\/now026","article-title":"Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas","volume":"18","author":"Pollack","year":"2016","journal-title":"Neuro Oncol"},{"key":"key20200713184553_b111-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1084\/jem.20171046","article-title":"Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy","volume":"215","author":"Chheda","year":"2018","journal-title":"J Exp Med"},{"key":"key20200713184553_b112-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"e1328340","DOI":"10.1080\/2162402X.2017.1328340","article-title":"K27M-mutant histone-3 as a novel target for glioma immunotherapy","volume":"6","author":"Ochs","year":"2017","journal-title":"Oncoimmunology"},{"key":"key20200713184553_b113-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"key20200713184553_b114-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","article-title":"The role of neoantigens in response to immune checkpoint blockade","volume":"28","author":"Riaz","year":"2016","journal-title":"Int Immunol"},{"key":"key20200713184553_b115-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"key20200713184553_b116-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"key20200713184553_b117-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","article-title":"B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma","volume":"111","author":"Zhou","year":"2013","journal-title":"J Neurooncol"},{"key":"key20200713184553_b118-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b119-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00432-010-0800-4","article-title":"Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients","volume":"136","author":"Lee","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20200713184553_b120-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br J Cancer"},{"key":"key20200713184553_b121-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-08-0536","article-title":"Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma","volume":"14","author":"Crispen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b122-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod Pathol"},{"key":"key20200713184553_b123-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b124-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.4049\/jimmunol.1301966","article-title":"Characterization of distinct immunophenotypes across pediatric brain tumor types","volume":"191","author":"Griesinger","year":"2013","journal-title":"J Immunol"},{"key":"key20200713184553_b125-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2013.06.005","article-title":"Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells","volume":"149","author":"Liu","year":"2013","journal-title":"Clin Immunol"},{"key":"key20200713184553_b126-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res"},{"key":"key20200713184553_b127-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1215\/15228517-2006-008","article-title":"The role of human glioma-infiltrating microglia\/macrophages in mediating antitumor immune responses","volume":"8","author":"Hussain","year":"2006","journal-title":"Neuro Oncol"},{"key":"key20200713184553_b128-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20200713184553_b129-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-06-2070","article-title":"Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function","volume":"13","author":"Fecci","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b130-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro Oncol"},{"key":"key20200713184553_b131-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"key20200713184553_b132-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1002\/cncr.26659","article-title":"A phase 2 study of pegylated interferon \u03b1-2b (PEG-Intron(\u00ae)) in children with diffuse intrinsic pontine glioma","volume":"118","author":"Warren","year":"2012","journal-title":"Cancer"},{"key":"key20200713184553_b133-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12964-016-0155-9","article-title":"Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation","volume":"15","author":"Greil","year":"2017","journal-title":"Cell Commun Signal"},{"key":"key20200713184553_b134-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1440-1711.1998.00717.x","article-title":"Tumour surveillance: Missing peptides and MHC molecules","volume":"76","author":"Khanna","year":"1998","journal-title":"Immunol Cell Biol"},{"key":"key20200713184553_b135-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"key":"key20200713184553_b136-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/sj.onc.1207373","article-title":"Regulation of apoptosis proteins in cancer cells by ubiquitin","volume":"23","author":"Zhang","year":"2004","journal-title":"Oncogene"},{"key":"key20200713184553_b137-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1044-579X(02)00131-1","article-title":"Cell surface Death Receptor signaling in normal and cancer cells","volume":"13","author":"Oz\u00f6ren","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"key20200713184553_b138-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/1440-1681.12732","article-title":"Increased PD-L1 expression in breast and colon cancer stem cells","volume":"44","author":"Wu","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key20200713184553_b139-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Oncoimmunology"},{"key":"key20200713184553_b140-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"key20200713184553_b141-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/107327481402100308","article-title":"PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy","volume":"21","author":"Dolan","year":"2014","journal-title":"Cancer Contr"},{"key":"key20200713184553_b142-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b143-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"9465","DOI":"10.1007\/s13277-015-4740-0","article-title":"B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway","volume":"37","author":"Jiang","year":"2016","journal-title":"Tumour Biol"},{"key":"key20200713184553_b144-ijo-52-04-1041","first-page":"1487","article-title":"Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness","volume":"26","author":"Silva","year":"2011","journal-title":"Histol Histopathol"},{"key":"key20200713184553_b145-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"10388","DOI":"10.1073\/pnas.1434299100","article-title":"B7x: a widely expressed B7 family member that inhibits T cell activation","volume":"100","author":"Zang","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b146-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713184553_b147-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nri.2017.46","article-title":"Immunosuppressive cell death in cancer","volume":"17","author":"Hou","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"key20200713184553_b148-ijo-52-04-1041","first-page":"1168","article-title":"Interleukin-13 receptor alpha chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas","volume":"60","author":"Joshi","year":"2000","journal-title":"Cancer Res"},{"key":"key20200713184553_b149-ijo-52-04-1041","first-page":"2851","article-title":"Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain","volume":"8","author":"Okano","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b150-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/sj.bjc.6600593","article-title":"UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour","volume":"87","author":"Tsuda","year":"2002","journal-title":"Br J Cancer"},{"key":"key20200713184553_b151-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/sj.bjc.6603696","article-title":"Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy","volume":"96","author":"Schmitz","year":"2007","journal-title":"Br J Cancer"},{"key":"key20200713184553_b152-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-04-1737","article-title":"Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients","volume":"11","author":"Heimberger","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b153-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/sj.onc.1207252","article-title":"Identification of a human glioma antigen, SOX6, recognized by patients' sera","volume":"23","author":"Ueda","year":"2004","journal-title":"Oncogene"},{"key":"key20200713184553_b154-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ijc.20929","article-title":"Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor-associated autoantibodies correlated with prolonged survival","volume":"117","author":"Pallasch","year":"2005","journal-title":"Int J Cancer"},{"key":"key20200713184553_b155-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.semcancer.2006.07.005","article-title":"Tumor and viral recognition by natural killer cells receptors","volume":"16","author":"Arnon","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"key20200713184553_b156-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11060-006-9265-3","article-title":"Expression of MHC I and NK ligands on human CD133+ glioma cells: Possible targets of immunotherapy","volume":"83","author":"Wu","year":"2007","journal-title":"J Neurooncol"},{"key":"key20200713184553_b157-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1093\/brain\/awl205","article-title":"TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells","volume":"129","author":"Eisele","year":"2006","journal-title":"Brain"},{"key":"key20200713184553_b158-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"12445","DOI":"10.1073\/pnas.93.22.12445","article-title":"Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium","volume":"93","author":"Groh","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b159-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1593\/neo.05277","article-title":"EphA2 as a glioma-associated antigen: A novel target for glioma vaccines","volume":"7","author":"Hatano","year":"2005","journal-title":"Neoplasia"},{"key":"key20200713184553_b160-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-06-1576","article-title":"Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics","volume":"13","author":"Zhang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b161-ijo-52-04-1041","first-page":"1277","article-title":"Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients","volume":"19","author":"Jin","year":"2008","journal-title":"Oncol Rep"},{"key":"key20200713184553_b162-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00002371-200405000-00006","article-title":"AIM-2: A novel tumor antigen is expressed and presented by human glioma cells","volume":"27","author":"Liu","year":"2004","journal-title":"J Immunother"},{"key":"key20200713184553_b163-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<760::AID-IJC11>3.0.CO;2-R","article-title":"Expression of the tumor-rejection antigen SART1 in brain tumors","volume":"83","author":"Imaizumi","year":"1999","journal-title":"Int J Cancer"},{"key":"key20200713184553_b164-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00002371-200009000-00001","article-title":"Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides","volume":"23","author":"Murayama","year":"2000","journal-title":"J Immunother"},{"key":"key20200713184553_b165-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1158\/0008-5472.CAN-03-3504","article-title":"HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells","volume":"64","author":"Liu","year":"2004","journal-title":"Cancer Res"},{"key":"key20200713184553_b166-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11060-006-9220-3","article-title":"Expression of nine tumour antigens in a series of human glioblastoma multiforme: Interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy","volume":"81","author":"Saikali","year":"2007","journal-title":"J Neurooncol"},{"key":"key20200713184553_b167-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/00002371-200307000-00002","article-title":"Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma","volume":"26","author":"Liu","year":"2003","journal-title":"J Immunother"},{"key":"key20200713184553_b168-ijo-52-04-1041","first-page":"2143","article-title":"Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas","volume":"150","author":"Chi","year":"1997","journal-title":"Am J Pathol"},{"key":"key20200713184553_b169-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"8304","DOI":"10.1158\/1078-0432.CCR-04-2588","article-title":"Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors","volume":"11","author":"Facoetti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b170-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b171-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/labinvest.3700233","article-title":"Downregulation of major histocompatibility complex antigens in invading glioma cells: Stealth invasion of the brain","volume":"85","author":"Zagzag","year":"2005","journal-title":"Lab Invest"},{"key":"key20200713184553_b172-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-007-0231-8","article-title":"WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: Does it reflect a potential immune escape mechanism","volume":"114","author":"Mehling","year":"2007","journal-title":"Acta Neuropathol"},{"key":"key20200713184553_b173-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/nop009","article-title":"TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients","volume":"12","author":"Crane","year":"2010","journal-title":"Neuro Oncol"},{"key":"key20200713184553_b174-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"key20200713184553_b175-ijo-52-04-1041","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.4049\/jimmunol.143.10.3222","article-title":"Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2","volume":"143","author":"Bodmer","year":"1989","journal-title":"J Immunol"},{"key":"key20200713184553_b176-ijo-52-04-1041","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/j.1460-2075.1987.tb02411.x","article-title":"T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta","volume":"6","author":"Wrann","year":"1987","journal-title":"EMBO J"},{"key":"key20200713184553_b177-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1158\/1535-7163.MCT-09-0734","article-title":"Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway","volume":"9","author":"Wei","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"key20200713184553_b178-ijo-52-04-1041","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/j.1460-2075.1987.tb02700.x","article-title":"Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family","volume":"6","author":"de Martin","year":"1987","journal-title":"EMBO J"},{"key":"key20200713184553_b179-ijo-52-04-1041","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","author":"Gide","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b180-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6074.TUMIMM16-A18","article-title":"Genomic and neoantigen evolution and resistance to immune checkpoint blockade in metastatic renal cell carcinoma","volume":"5","author":"Miao","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"key20200713184553_b181-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"e30676","DOI":"10.1371\/journal.pone.0030676","article-title":"TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"key":"key20200713184553_b182-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"key":"key20200713184553_b183-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"key20200713184553_b184-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","article-title":"Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy","volume":"9","author":"\u015aledzi\u0144ska","year":"2015","journal-title":"Mol Oncol"},{"key":"key20200713184553_b185-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b186-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"key20200713184553_b187-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"key20200713184553_b188-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"key20200713184553_b189-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"key20200713184553_b190-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713184553_b191-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-13-1253","article-title":"Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy","volume":"19","author":"Beard","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20200713184553_b192-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/jnen\/nlx042","article-title":"Multiplex detection of pediatric low-grade glioma signature fusion transcripts and duplications using the NanoString nCounter system","volume":"76","author":"Ryall","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"key":"key20200713184553_b193-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","article-title":"Mutant IDH1 and seizures in patients with glioma","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"key20200713184553_b194-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.15252\/embj.201695429","article-title":"ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells","volume":"36","author":"Bassoy","year":"2017","journal-title":"EMBO J"},{"key":"key20200713184553_b195-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"9366","DOI":"10.18632\/oncotarget.14070","article-title":"Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor","volume":"8","author":"Wells","year":"2017","journal-title":"Oncotarget"},{"key":"key20200713184553_b196-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.humpath.2016.08.007","article-title":"Progression of atypical extraventricular neurocytoma to anaplastic ganglioglioma","volume":"59","author":"Rusiecki","year":"2017","journal-title":"Hum Pathol"},{"key":"key20200713184553_b197-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40478-016-0353-0","article-title":"Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma","volume":"4","author":"Ryall","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"key20200713184553_b198-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: A Canadian Pediatric Brain Tumor Consortium Study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20200713184553_b199-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"e87059","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight"},{"key":"key20200713184553_b200-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"42837","DOI":"10.18632\/oncotarget.10034","article-title":"Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: A case report","volume":"7","author":"Nazarian","year":"2016","journal-title":"Oncotarget"},{"key":"key20200713184553_b201-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"aad3018","DOI":"10.1126\/science.aad3018","article-title":"The tumor micro-environment underlies acquired resistance to CSF-1R inhibition in gliomas","volume":"352","author":"Quail","year":"2016","journal-title":"Science"},{"key":"key20200713184553_b202-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1210\/jc.2015-3889","article-title":"Pheotype: A diagnostic gene-expression assay for the classification of pheochromocytoma and paraganglioma","volume":"101","author":"Flynn","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200713184553_b203-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"e111783","DOI":"10.1371\/journal.pone.0111783","article-title":"Identification of molecular pathways facilitating glioma cell invasion in situ","volume":"9","author":"Nevo","year":"2014","journal-title":"PLoS One"},{"key":"key20200713184553_b204-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"key20200713184553_b205-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/neuonc\/not055","article-title":"MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells","volume":"15","author":"Peruzzi","year":"2013","journal-title":"Neuro Oncol"},{"key":"key20200713184553_b206-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.18632\/oncotarget.689","article-title":"Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma","volume":"3","author":"Kannan","year":"2012","journal-title":"Oncotarget"},{"key":"key20200713184553_b207-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"key20200713184553_b208-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"key20200713184553_b209-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"key20200713184553_b210-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.drudis.2015.06.001","article-title":"Impact of recent innovations in the use of mass cytometry in support of drug development","volume":"20","author":"Nassar","year":"2015","journal-title":"Drug Discov Today"},{"key":"key20200713184553_b211-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.1198704","article-title":"Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum","volume":"332","author":"Bendall","year":"2011","journal-title":"Science"},{"key":"key20200713184553_b212-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"key20200713184553_b213-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"key20200713184553_b214-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/neuonc\/nos295","article-title":"Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma","volume":"15","author":"Omuro","year":"2013","journal-title":"Neuro Oncol"},{"key":"key20200713184553_b215-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/1570159X14666160509123229","article-title":"Diffuse Intrinsic Pontine Glioma: New pathophysiological insights and emerging therapeutics targets","volume":"15","author":"Johung","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"key20200713184553_b216-ijo-52-04-1041","first-page":"2008","volume-title":"Holland Frei Cancer Medicine","author":"Bast","year":"2017","edition":"9th"},{"key":"key20200713184553_b217-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20130590","article-title":"Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy","volume":"211","author":"Fan","year":"2014","journal-title":"J Exp Med"},{"key":"key20200713184553_b218-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1073\/pnas.0806075105","article-title":"CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184553_b219-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"key20200713184553_b220-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13073-016-0365-1","article-title":"Acquired resistance to anti-PD1 therapy: Checkmate to checkpoint blockade?","volume":"8","author":"O'Donnell","year":"2016","journal-title":"Genome Med"},{"key":"key20200713184553_b221-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"key20200713184553_b222-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20200713184553_b223-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200713184553_b224-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"key20200713184553_b225-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"key20200713184553_b226-ijo-52-04-1041","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:42:20Z","timestamp":1693554140000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2018.4283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":226,"URL":"https:\/\/doi.org\/10.3892\/ijo.2018.4283","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]}}}